|
Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma Clinical research trials and Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma. Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma clinical trial. Test subjects typically obtain the finest healthcare available for their Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma  Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma
Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma
For Condition: Multiple Myeloma
Status: No longer recruiting
Sponsor(s): Medical Research Council ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating older patients with multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without cyclophosphamide and prednisone in treating older patients with multiple myeloma.
Details: OBJECTIVES: I. Compare the efficacy of doxorubicin, carmustine, cyclophosphamide, and melphalan (ABCM) with or without oral cyclophosphamide and prednisone as induction for the first plateau phase in elderly patients with previously untreated multiple myeloma. PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center. Patients receive doxorubicin IV followed immediately by carmustine IV over 1-2 hours on day 1 and oral melphalan (L-PAM) and oral cyclophosphamide (CTX) on days 22-25 (ABCM). Treatment continues every 6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients whose blood counts recover within 6 weeks after beginning L-PAM and CTX during course 3 are randomized to 1 of 2 treatment arms. Patients whose blood counts fail to recover within 6 weeks after beginning L-PAM and CTX during course 3 are assigned to arm II. Arm I: Patients continue ABCM for a maximum of 12 courses in the absence of a plateau phase after completion of at least 4 courses, disease progression, or unacceptable toxicity. Arm II: Patients receive oral cyclophosphamide once weekly and oral prednisone every other day. Treatment continues every 6 weeks in the absence of a plateau phase after completion of 3 courses of ABCM plus a minimum of 8 weeks on arm II or less than 3 courses of ABCM plus 6 months on arm II, disease progression, or unacceptable toxicity. Patients on both arms with bone pain or failure to respond to chemotherapy may undergo minimal radiotherapy. Patients achieving plateau phase may enter the MRC trial of interferon alfa-2b. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 1,000 patients will be accrued for this study within approximately 5 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 65 Years/74 Years
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Diagnosis of multiple myeloma, defined by at least 2 of the following conditions: - Neoplastic cell infiltrate and/or microplasmacytomas by bone marrow sections or smears. Plasma cell infiltrates greater than 20% of marrow nucleated cells or, if less than 20%, objective evidence of monoclonality of the plasma cells required - Paraprotein in blood or urine - Definite lytic bone lesions (not osteoporosis) Nonsecretory disease allowed in the presence of 1 of the following conditions: - Microplasmacytomas - Monoclonal plasmacytosis with immunoglobulin light-chain expression in cytoplasm No equivocal myelomatosis, defined by the following criteria: - Minimal or no symptoms attributable to myelomatosis - Pretransfusion hemoglobin greater than 10 g/dL - Post-hydration creatinine less than 1.47 mg/dL - No osteolytic lesions except minimal lesions that do not threaten pathological fracture and are not associated with pain - Plasma cells less than 30% of marrow nucleated cells and marrow showing normal hematopoietic activity - Serum beta-2 microglobulin less than 4 mg/L - Less than 1 g of free light-chain excretion per 1 g of creatinine - No objective factors indicating progressive myelomatosis --Prior/Concurrent Therapy-- Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Prior or concurrent prednisolone at 30 mg/m2/day or less (or equivalent doses of other corticosteroids) for relief of fluid-unresponsive hypercalcemia allowed Radiotherapy: Prior or concurrent minimal local radiotherapy to relieve persistent bone pain or cord compression allowed Surgery: Not specified --Patient Characteristics-- Age: - 65 to 74 - If under 65, higher priority is given to protocol MRC-LEUK-MYEL-VII unless entry into this study would be more appropriate Performance status: Not specified Life expectancy: Not specified Hematopoietic: - See Disease Characteristics - Neutrophil count at least 1,300/mm3 - Platelet count at least 75,000/mm3 Hepatic: Not specified Renal: See Disease Characteristics Other: - Ability to tolerate fluid intake of at least 3 L/day beginning at least 2 days before study entry - Afebrile and free of infection - No contraindication to therapy
Total Enrollment:
Location and Contact Information:
Overall Study Official:
M.T.Drayson, Study Chair, Medical Research Council
MRC Myelomatosis Trials Office
Birmingham, England, B15 2SZ
United Kingdom
Additional Information:
Study ID Numbers: CDR0000064187; MRC-LEUK-MYEL-VIII,EU-94031
Study Start Date: September 1993
Record last reviewed: April 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002653
Other Multiple Myeloma Studies:
1. Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
2. Stem Cell Transplant for Patients with Blood Malignancy Using Donors and Less Toxic Chemotherapy with CAMPATH 1H
3. Study comparing safety and efficacy of STR + melphalan to melphalan alone, with stem cell transplant in multiple myeloma
4. Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
5. Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
Related Studies:
Other Multiple Myeloma Clinical Trials
Other England Clinical Trials
Other Birmingham Clinical Trials
Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma
|
|
|
|
|
|
|
|
